However, another study that included 1514 patients undergoing allogenic hematopoietic stem cell transplant with MDS revealed that TP53 mutations, RAS pathway mutations, and JAK2 mutations were associated with a shorter survival [24] While the mechanism of the JAK2 mutation is unknown, interestingly, the patients with JAK2 mutations were associated with a higher rate of death without relapse regardless of conditioning intensity suggesting the significance of using JAK2 inhibitors in this subset of patients [24] (Table 1). Here, JAK2 is linked to myelodysplastic syndrome.